Program
Prazosin
Also written as “Prazosin HCl”, “Prazosin HCl 2mg” and “Prazosin HCl 1 mg”.
Its studies are mostly in Hypertension · Stress Disorders, Post-Traumatic, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 20 open or running | phase 1since Jul 8, 2021 | Jul 8, 2021 | none ahead |
| Haffkine Bio-Pharmaceutical | 10 open or running | phase 3since Sep 14, 2008 | Sep 14, 2008 | none ahead |
| Otsuka | 10 open or running | phase 1since Oct 22, 2021 | Oct 22, 2021 | none ahead |
Also a collaborator on its studies: iqvia-pty-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 14, 2008First study: phase 3 study in Scorpion StingsNew to Haffkine Bio-PharmaceuticalHaffkine Bio-Pharmaceutical · NCT00753064 · 81 enrolled · India
- Jul 8, 2021Pfizer's first study: phase 1 study in HypertensionNew to PfizerPfizer · NCT04967443 · 72 enrolled · United States
- Oct 22, 2021Otsuka's first study: phase 1 study in Stress Disorders, Post-TraumaticNew to OtsukaOtsuka · NCT05189977 · 34 enrolled · United States
- Nov 13, 2025Phase 1 study in HealthyPfizer · NCT07231978 · 69 enrolled · Belgium
TargetBeta
“Adrenergic receptor alpha-1 antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tamsulosinrule | Boehringer Ingelheim | phase 4 | 60 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| Midodrinerule | Takeda | phase 4 | 10 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07231978Healthy · Belgium | 1 | Completed | Pfizer | Apr 3, 2026 | 69 |
| NCT05189977Stress Disorders, Post-Traumatic · United States | 1 | Terminated | Otsuka | Aug 3, 2023 | 34 |
| NCT04967443Hypertension · United States | 1 | Completed | Pfizer | Feb 15, 2022 | 72 |
| NCT00753064Scorpion Stings · India | 3 | Completed | Haffkine Bio-Pharmaceutical | Dec 2007 | 81 |
How it is read
Names in the registry
- “Prazosin HCl”, 1 entry
- “Prazosin HCl 2mg”, 1 entry
- “Prazosin HCl 1 mg”, 1 entry
- “Prazosin”, 1 entry
- “AScVS + Prazosin”, 1 entry
Conditions, from the studies’ own filings
- Hypertension, 1 study
- Stress Disorders, Post-Traumatic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.